The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monday Deal Review: July 20, 2009

B&W_BigNickelThis week’s deal review has some more info about Ambrilia’s deal with Kotinos that I tweeted about at the time (my Twitter stream shows up in the sidebar on the right here), as well as an update on JLL-Patheon and a raft of securities deals, including an issuer bid

M&A:

Private Placements:

Issuer Bid:

Bradmer Pharmaceuticals Inc. (TSX: BMR) is launching a substantial issuer bid to purchase up to 8,300,000 of its 13,488,215 outstanding common shares for cancellation at a price of Cdn$0.20 per share, which will be funded by Bradmer out of cash on hand. Full details of the Offer will be in the issuer bid circular and other related documents (which aren’t up on SEDAR yet, but will be here when they are).  Bloom Burton & Co is providing the formal valuation.  Bradmer has been notified that the TSX is reviewing its eligibility for continued listing of the common shares and has until February 8, 2010 to satisfy the exchange’s requirements. Bradmer may transfer its listing to the TSX Venture Exchange or the NEX Board of the TSX Venture Exchange.

Share Button

About these ads

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 126 other followers